<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37131073</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis.</ArticleTitle><Pagination><StartPage>2872</StartPage><EndPage>2877</EndPage><MedlinePgn>2872-2877</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-023-02084-1</ELocationID><Abstract><AbstractText>In the aftermath of the COVID-19 pandemic, we are witnessing an unprecedented wave of post-infectious complications. Most prominently, millions of patients with Long-Covid complain about chronic fatigue and severe post-exertional malaise. Therapeutic apheresis has been suggested as an efficient treatment option for alleviating and mitigating symptoms in this desperate group of patients. However, little is known about the mechanisms and biomarkers correlating with treatment outcomes. Here, we have analyzed in different cohorts of Long-Covid patients specific biomarkers before and after therapeutic apheresis. In patients that reported a significant improvement following two cycles of therapeutic apheresis, there was a significant reduction in neurotransmitter autoantibodies, lipids, and inflammatory markers. Furthermore, we observed a 70% reduction in fibrinogen, and following apheresis, erythrocyte rouleaux formation and fibrin fibers largely disappeared as demonstrated by dark field microscopy. This is the first study demonstrating a pattern of specific biomarkers with clinical symptoms in this patient group. It may therefore form the basis for a more objective monitoring and a clinical score for the treatment of Long-Covid and other postinfectious syndromes.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Achleitner</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Steenblock</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9635-4860</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany. charlotte.steenblock@uniklinikum-dresden.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xe4;nhardt</LastName><ForeName>Juliane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarzebska</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kardashi</LastName><ForeName>Romina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanczkowski</LastName><ForeName>Waldemar</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Straube</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Zentrum f&#xfc;r Apherese- und H&#xe4;mofiltration am INUS Tageklinikum, Cham, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodionov</LastName><ForeName>Roman N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bornstein</LastName><ForeName>Nitzan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tselmin</LastName><ForeName>Sergey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Alpstein Clinic, Gais, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bucher</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biologicum Baden-Baden INUSpherese Zentrum, Baden-Baden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbir</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Harefield Hospital, Harefield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Ma-Li</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, College of Medicine, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience &amp; Physiology, College of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voit-Bak</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Zentrum f&#xfc;r Apherese- und H&#xe4;mofiltration am INUS Tageklinikum, Cham, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Licinio</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, College of Medicine, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience &amp; Physiology, College of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bornstein</LastName><ForeName>Stefan R</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0002-5211-2536</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences &amp; Medicine, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH), Zurich, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>314061271</GrantID><Agency>Deutsche Forschungsgemeinschaft (German Research Foundation)</Agency><Country/></Grant><Grant><GrantID>288034826</GrantID><Agency>Deutsche Forschungsgemeinschaft (German Research Foundation)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008077">Lipoproteins, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008077" MajorTopicYN="N">Lipoproteins, LDL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001781" MajorTopicYN="Y">Blood Component Removal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>1</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>2</Day><Hour>23</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37131073</ArticleId><ArticleId IdType="pmc">PMC10152027</ArticleId><ArticleId IdType="doi">10.1038/s41380-023-02084-1</ArticleId><ArticleId IdType="pii">10.1038/s41380-023-02084-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bornstein SR, Cozma D, Kamel M, Hamad M, Mohammad MG, Khan NA, et al. Long-COVID, metabolic and endocrine disease. Horm Metab Res. 2022;54:562&#x2013;6. doi: 10.1055/a-1878-9307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1878-9307</ArticleId><ArticleId IdType="pmc">PMC9363148</ArticleId><ArticleId IdType="pubmed">35724687</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10:863&#x2013;76. doi: 10.1016/S2213-2600(22)00126-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger BR, Arron HE, Kalka-Moll WM, Seidel D. The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19. Front Cardiovasc Med. 2022;9:1007636. doi: 10.3389/fcvm.2022.1007636.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.1007636</ArticleId><ArticleId IdType="pmc">PMC9592739</ArticleId><ArticleId IdType="pubmed">36304538</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel J, Ramlow A, Bock C, Sheriff A. Case report: C-reactive protein apheresis in a patient with COVID-19 and fulminant CRP increase. Front Immunol. 2021;12:708101. doi: 10.3389/fimmu.2021.708101.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.708101</ArticleId><ArticleId IdType="pmc">PMC8366396</ArticleId><ArticleId IdType="pubmed">34408751</ArticleId></ArticleIdList></Reference><Reference><Citation>Steenblock C, Walther R, Tselmin S, Jarzebska N, Voit-Bak K, Toepfner N, et al. Post COVID and apheresis - where are we standing? Horm Metab Res. 2022;54:715&#x2013;20. doi: 10.1055/a-1945-9694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1945-9694</ArticleId><ArticleId IdType="pubmed">36113501</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong AD, Auld SC, Barker NA, Friend S, Wynn AT, Cobb J, et al. Therapeutic plasma exchange for COVID-19-associated hyperviscosity. Transfusion. 2021;61:1029&#x2013;34. doi: 10.1111/trf.16218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16218</ArticleId><ArticleId IdType="pmc">PMC7753437</ArticleId><ArticleId IdType="pubmed">33231313</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi K. Long covid and apheresis: a miracle cure sold on a hypothesis of hope. BMJ. 2022;378:o1733. doi: 10.1136/bmj.o1733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o1733</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies M. Long covid patients travel abroad for expensive and experimental &#x201c;blood washing&#x201d;. BMJ. 2022;378:o1671. doi: 10.1136/bmj.o1671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o1671</ArticleId><ArticleId IdType="pubmed">35820689</ArticleId></ArticleIdList></Reference><Reference><Citation>Charfeddine S, Ibn Hadj Amor H, Jdidi J, Torjmen S, Kraiem S, Hammami R, et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV Study. Front Cardiovasc Med. 2021;8:745758. doi: 10.3389/fcvm.2021.745758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.745758</ArticleId><ArticleId IdType="pmc">PMC8670225</ArticleId><ArticleId IdType="pubmed">34917659</ArticleId></ArticleIdList></Reference><Reference><Citation>Balcom EF, Nath A, Power C. Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. Brain. 2021;144:3576&#x2013;88. doi: 10.1093/brain/awab302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab302</ArticleId><ArticleId IdType="pmc">PMC8719840</ArticleId><ArticleId IdType="pubmed">34398188</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76:e487&#x2013;e490. doi: 10.1093/cid/ciac722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldhaleei WA, Alnuaimi A, Bhagavathula AS. COVID-19 induced hepatitis B virus reactivation: a novel case from the United Arab Emirates. Cureus. 2020;12:e8645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296884</ArticleId><ArticleId IdType="pubmed">32550096</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto I, Biagioni E, Coloretti I, Farinelli C, Avoni C, Caciagli V, et al. Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality. Intensive Care Med. 2022;48:706&#x2013;13. doi: 10.1007/s00134-022-06716-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-022-06716-y</ArticleId><ArticleId IdType="pmc">PMC9116062</ArticleId><ArticleId IdType="pubmed">35583676</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng M, Zhang S, Dong X, Sun W, Deng Y, Li W, et al. COVID-19 associated EBV reactivation and effects of ganciclovir treatment. Immun Inflamm Dis. 2022;10:e597. doi: 10.1002/iid3.597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.597</ArticleId><ArticleId IdType="pmc">PMC8959425</ArticleId><ArticleId IdType="pubmed">35349757</ArticleId></ArticleIdList></Reference><Reference><Citation>Shariq M, Sheikh JA, Quadir N, Sharma N, Hasnain SE, Ehtesham NZ. COVID-19 and tuberculosis: the double whammy of respiratory pathogens. Eur Respir Rev. 2022;31:210264. doi: 10.1183/16000617.0264-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0264-2021</ArticleId><ArticleId IdType="pmc">PMC9488123</ArticleId><ArticleId IdType="pubmed">35418488</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubchenko S, Kril I, Nadizhko O, Matsyura O, Chopyak V. Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol Int. 2022;42:1523&#x2013;30. doi: 10.1007/s00296-022-05146-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05146-9</ArticleId><ArticleId IdType="pmc">PMC9159383</ArticleId><ArticleId IdType="pubmed">35650445</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobasheri L, Nasirpour MH, Masoumi E, Azarnaminy AF, Jafari M, Esmaeili SA. SARS-CoV-2 triggering autoimmune diseases. Cytokine. 2022;154:155873. doi: 10.1016/j.cyto.2022.155873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2022.155873</ArticleId><ArticleId IdType="pmc">PMC8979824</ArticleId><ArticleId IdType="pubmed">35461172</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahabi M, Ghazanfari T, Sepehrnia S. Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection. Int Immunopharmacol. 2022;112:109183. doi: 10.1016/j.intimp.2022.109183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.109183</ArticleId><ArticleId IdType="pmc">PMC9393178</ArticleId><ArticleId IdType="pubmed">36182877</ArticleId></ArticleIdList></Reference><Reference><Citation>Zebardast A, Hasanzadeh A, Ebrahimian Shiadeh SA, Tourani M, Yahyapour Y. COVID-19: a trigger of autoimmune diseases. Cell Biol Int. 2023;47:848&#x2013;58. doi: 10.1002/cbin.11997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbin.11997</ArticleId><ArticleId IdType="pubmed">36740221</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28:911&#x2013;23. doi: 10.1038/s41591-022-01810-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Marques O, Halpert G, Schimke LF, Ostrinski Y, Vojdani A, Baiocchi GC, et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat Commun. 2022;13:1220. doi: 10.1038/s41467-022-28905-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28905-5</ArticleId><ArticleId IdType="pmc">PMC8907309</ArticleId><ArticleId IdType="pubmed">35264564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, Furst J, Schulze-Rothe S, Wallukat A, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Joob B, Wiwanitkit V. Blood viscosity of COVID-19 patient: a preliminary report. Am J Blood Res. 2021;11:93&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010604</ArticleId><ArticleId IdType="pubmed">33796395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kub&#xe1;nkov&#xe1; M, Hohberger B, Hoffmanns J, F&#xfc;rst J, Herrmann M, Guck J, et al. Physical phenotype of blood cells is altered in COVID-19. Biophys J. 2021;120:2838&#x2013;47. doi: 10.1016/j.bpj.2021.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2021.05.025</ArticleId><ArticleId IdType="pmc">PMC8169220</ArticleId><ArticleId IdType="pubmed">34087216</ArticleId></ArticleIdList></Reference><Reference><Citation>Osiaevi I, Schulze A, Evers G, Harmening K, Vink H, K&#xfc;mpers P et al. Persistent capillary rarefication in long COVID syndrome. Angiogenesis. 2023:26:53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9366128</ArticleId><ArticleId IdType="pubmed">35951203</ArticleId></ArticleIdList></Reference><Reference><Citation>de Arriba Fern&#xe1;ndez A, Alonso Bilbao JL, Espi&#xf1;eira Franc&#xe9;s A, Cabeza Mora A, Guti&#xe9;rrez P&#xe9;rez &#xc1;, D&#xed;az Barreiros M, et al. Assessment of SARS-CoV-2 infection according to previous metabolic status and its association with mortality and post-acute COVID-19. Nutrients. 2022;14:2925. doi: 10.3390/nu14142925.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14142925</ArticleId><ArticleId IdType="pmc">PMC9325256</ArticleId><ArticleId IdType="pubmed">35889880</ArticleId></ArticleIdList></Reference><Reference><Citation>Loosen SH, Jensen BO, Tanislav C, Luedde T, Roderburg C, Kostev K. Obesity and lipid metabolism disorders determine the risk for development of long COVID syndrome: a cross-sectional study from 50,402 COVID-19 patients. Infection. 2022;50:1165&#x2013;70. doi: 10.1007/s15010-022-01784-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-022-01784-0</ArticleId><ArticleId IdType="pmc">PMC8966865</ArticleId><ArticleId IdType="pubmed">35355237</ArticleId></ArticleIdList></Reference><Reference><Citation>Stasiak A, Perdas E, Smolewska E. Risk factors of a severe course of pediatric multi-system inflammatory syndrome temporally associated with COVID-19. Eur J Pediatr. 2022;181:3733&#x2013;8. doi: 10.1007/s00431-022-04584-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-022-04584-8</ArticleId><ArticleId IdType="pmc">PMC9364844</ArticleId><ArticleId IdType="pubmed">35948653</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E, Xie Y, Al-Aly Z. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2023;11:120&#x2013;8. doi: 10.1016/S2213-8587(22)00355-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00355-2</ArticleId><ArticleId IdType="pmc">PMC9873268</ArticleId><ArticleId IdType="pubmed">36623520</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopprasch S, Bornstein SR, Schwarz PE, Bergmann S, Julius U, Graessler J. Single whole blood dextran sulfate adsorption favorably affects systemic oxidative balance in lipoprotein apheresis patients. Atheroscler Suppl. 2013;14:157&#x2013;60. doi: 10.1016/j.atherosclerosissup.2012.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosissup.2012.10.007</ArticleId><ArticleId IdType="pubmed">23357158</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopprasch S, Graessler J, Bornstein SR, Schwarz PE, Tselmin S, Frind A, et al. Beyond lowering circulating LDL: apheresis-induced changes of systemic oxidative stress markers by four different techniques. Atheroscler Suppl. 2009;10:34&#x2013;38. doi: 10.1016/S1567-5688(09)71807-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1567-5688(09)71807-0</ArticleId><ArticleId IdType="pubmed">20129371</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xe4;&#xdf;ler J, Kopprasch S, Passauer J, Fischer S, Schuhmann K, Bergmann S, et al. Differential effects of lipoprotein apheresis by lipidfiltration or dextran sulfate adsorption on lipidomic profile. Atheroscler Suppl. 2013;14:151&#x2013;5. doi: 10.1016/j.atherosclerosissup.2012.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosissup.2012.10.006</ArticleId><ArticleId IdType="pubmed">23357157</ArticleId></ArticleIdList></Reference><Reference><Citation>Julius U, Siegert G, Kostka H, Schatz U, Hohenstein B. Effects of different lipoprotein apheresis methods on serum protein levels. Atheroscler Suppl. 2015;18:95&#x2013;102. doi: 10.1016/j.atherosclerosissup.2015.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosissup.2015.02.018</ArticleId><ArticleId IdType="pubmed">25936311</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohenstein B, Passauer J, Ziemssen T, Julius U. Immunoadsorption with regenerating systems in neurological disorders -A single center experience. Atheroscler Suppl. 2015;18:119&#x2013;23. doi: 10.1016/j.atherosclerosissup.2015.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosissup.2015.02.022</ArticleId><ArticleId IdType="pubmed">25936315</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology. 2012;51:60&#x2013;68. doi: 10.1093/rheumatology/ker162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ker162</ArticleId><ArticleId IdType="pubmed">21515629</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber-Fishkin S, Seidner HS, Gunter G, Frame MD. Erythrocyte aggregation in sudden flow arrest is linked to hyperthermia, hypoxemia, and band 3 availability. J Thromb Haemost. 2022;20:2284&#x2013;92. doi: 10.1111/jth.15821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15821</ArticleId><ArticleId IdType="pubmed">35841276</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasini E, Corsetti G, Romano C, Scarabelli TM, Chen-Scarabelli C, Saravolatz L, et al. Serum metabolic profile in patients with long-covid (PASC) syndrome: clinical implications. Front Med. 2021;8:714426. doi: 10.3389/fmed.2021.714426.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.714426</ArticleId><ArticleId IdType="pmc">PMC8339407</ArticleId><ArticleId IdType="pubmed">34368201</ArticleId></ArticleIdList></Reference><Reference><Citation>Straube R, Voit-Bak K, Gor A, Steinmeier T, Chrousos GP, Boehm BO, et al. Lipid profiles in lyme borreliosis: a potential role for apheresis? Horm Metab Res. 2019;51:326&#x2013;9. doi: 10.1055/a-0885-7169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-0885-7169</ArticleId><ArticleId IdType="pubmed">31071737</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X, Takov K, Straube R, Voit-Bak K, Graessler J, Julius U, et al. Precision medicine approach for cardiometabolic risk factors in therapeutic apheresis. Horm Metab Res. 2022;54:238&#x2013;49. doi: 10.1055/a-1776-7943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1776-7943</ArticleId><ArticleId IdType="pubmed">35413745</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollbracht C, Kraft K. Feasibility of vitamin C in the treatment of post viral fatigue with focus on long COVID, based on a systematic review of IV vitamin C on fatigue. Nutrients. 2021;13:1154. doi: 10.3390/nu13041154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13041154</ArticleId><ArticleId IdType="pmc">PMC8066596</ArticleId><ArticleId IdType="pubmed">33807280</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne CJ, Khurana S, Kumar A, Tai TC. Inflammatory signaling in hypertension: regulation of adrenal catecholamine biosynthesis. Front Endocrinol. 2018;9:343. doi: 10.3389/fendo.2018.00343.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2018.00343</ArticleId><ArticleId IdType="pmc">PMC6036303</ArticleId><ArticleId IdType="pubmed">30013513</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluge &#xd8;, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, et al. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One. 2011;6:e26358. doi: 10.1371/journal.pone.0026358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026358</ArticleId><ArticleId IdType="pmc">PMC3198463</ArticleId><ArticleId IdType="pubmed">22039471</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluge &#xd8;, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D, et al. B-lymphocyte depletion in myalgic encephalopathy/ chronic fatigue syndrome. an open-label phase II study with rituximab maintenance treatment. PLoS One. 2015;10:e0129898. doi: 10.1371/journal.pone.0129898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0129898</ArticleId><ArticleId IdType="pmc">PMC4488509</ArticleId><ArticleId IdType="pubmed">26132314</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>